Type:Injection
Generic Name:Aminocaproic Acid
Manufacturer:EDCL
Price:৳25.00
Intravenous Treatment and prophylaxis of haemorrhage Adult: Initially, 4-5 g as a 2% solution over 1 hr followed by a 1 g/hr infusion continued for up to 8 hr or until bleeding has been controlled. Max: 24 g in 24 hr. Oral Treatment and prophylaxis of haemorrhage Adult: Initially, 4-5 g, followed by 1-1.25 g every hr for about 8 hr or until bleeding has been controlled. Max: 24 g in 24 hr. Patients with haemophilia undergoing dental extraction Adult: Initially, 6 g immediately after the procedure, followed by 6 g every 6 hr for up to 10 days.
Increased risk of hypercoagulability with OC and oestrogens.
Renal or cardiac disorders. Urinary tract bleeding, haematuria of upper urinary tract origin; veno-occlusive hepatic disease, skeletal myopathy, neonates. Monitor creatinine phosphokinase. Avoid admin with factor IX complex concentrates. Pregnancy and lactation. Lactation: not known whether excreted in breast milk, use caution
Aminocaproic acid inhibits the action of plasminogen activators and, to a lesser extent, it also has some antiplasmin activity.
IV Administration Initial 5 g in 250 mL over 1 hr, each subsequent gram in 50-100 mL at 1 g/hr Rapid injection undiluted into a vein is not recommended Continue for about 8 hr or until bleeding has been controlled Oral May be taken with or without food. May be taken w/ meals to prevent GI upset.
Haemorrhage, Missed abortion, Hereditary hemorrhagic telangiectasia,Traumatic hyphema, Dental bleeding, Hemophilia A, Postoperative bleeding, Systemic hyperfibrinolysis
Renal impairment: Dosage reduction may be required.
Oedema, headache, malaise, allergic and anaphylactic reactions, anaphylaxis, bradycardia, hypotension, peripheral ischaemia, thrombosis, abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, coagulation disorder, leukopaenia, thrombocytopaenia, increased CPK, muscle damage, myalgia, myopathy, myositis, rhabdomyolysis, confusion, convulsions, delirium, dizziness, hallucinations, intracranial hypertension, stroke, syncope, dyspnoea, nasal congestion, pulmonary embolism, pruritus, rash, tinnitus, decreased vision, watery eyes, increased BUN, dry ejaculation. Potentially Fatal: Cardiac and hepatic damage.
Bleeding due to disseminated intravascular coagulation. Rapid IV administration.
